Tag Archives: colorectal_cancer

No Survival Benefit with Erbitux in Pancreatic Cancer

April 12, 2007 – 5:39 am

BOSTON APR 10, 2007 (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of Erbitux (cetuximab) failed to extend survival in patients with pancreatic cancer.
Erbitux is already approved to treat colorectal cancer and head and neck cancer.
The 700-patient trial compared Erbitux in combination with gemcitabine to gemcitabine alone in patients with pancreatic […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , | Comments (0)

ImClone’s Erbitux flunks new cancer trial

April 11, 2007 – 7:45 am

BOSTON (Reuters) — ImClone Systems Inc. said Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with pancreatic cancer, sending its shares down more than 7.5 percent.
Erbitux, which is already approved to treat colorectal cancer and head and neck cancer, and generated worldwide sales of $1.1 billion in […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , , | Comments (0)

Insurance Companies Resisting in the Prevention of Colon Cancer

April 2, 2007 – 5:21 pm

There are a total of four government recommended screenings in the prevention of Colon Cancer. While most insurance companies cover all of these, there are a few holdouts. Now, the cancer advocacy groups are pushing them to join the fight against cancer, as well.
Fifteen states are considering legislative mandates, by the American Cancer Society’s count, […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , , | Comments (0)

Long-Term Aspirin Use Lowers Death Rate in Women

March 30, 2007 – 7:56 am

Researchers affiliated with the Nurses’ Health Study have reported that low to moderate doses of aspirin are associated with a lower all cause mortality. A modest benefit on cancer deaths was only seen after 10 years of usage. The details of this study appeared in the March 26, 2007 issue of the Archives of Internal […]

By DotCancer.Com | Posted in Dotcancer | Also tagged , | Comments (0)